BR112022009142A2 - Derivados de indol macrocíclicos como inibidores de mcl-1 - Google Patents

Derivados de indol macrocíclicos como inibidores de mcl-1

Info

Publication number
BR112022009142A2
BR112022009142A2 BR112022009142A BR112022009142A BR112022009142A2 BR 112022009142 A2 BR112022009142 A2 BR 112022009142A2 BR 112022009142 A BR112022009142 A BR 112022009142A BR 112022009142 A BR112022009142 A BR 112022009142A BR 112022009142 A2 BR112022009142 A2 BR 112022009142A2
Authority
BR
Brazil
Prior art keywords
mcl
inhibitors
macrocyclic
indol derivatives
indol
Prior art date
Application number
BR112022009142A
Other languages
English (en)
Inventor
Jan Rita Rombouts Frederik
Christian Albert Ghislain De Boeck Benoît
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112022009142A2 publication Critical patent/BR112022009142A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

DERIVADOS DE INDOL MACROCÍCLICOS COMO INIBIDORES DE MCL-1. A presente invenção refere-se a agentes farmacêuticos úteis para terapia e/ou profilaxia em um indivíduo, composição farmacêutica compreendendo tais compostos e ao seu uso como inibidores da MCL-1, úteis para tratar doenças como o câncer.
BR112022009142A 2019-11-21 2020-11-20 Derivados de indol macrocíclicos como inibidores de mcl-1 BR112022009142A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19210710 2019-11-21
PCT/EP2020/082900 WO2021099579A1 (en) 2019-11-21 2020-11-20 Macrocyclic indole derivatives as mcl-1 inhibitors

Publications (1)

Publication Number Publication Date
BR112022009142A2 true BR112022009142A2 (pt) 2022-07-26

Family

ID=68653380

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009142A BR112022009142A2 (pt) 2019-11-21 2020-11-20 Derivados de indol macrocíclicos como inibidores de mcl-1

Country Status (10)

Country Link
US (1) US20230021562A1 (pt)
EP (1) EP4061819A1 (pt)
JP (1) JP2023502699A (pt)
KR (1) KR20220103984A (pt)
CN (1) CN114728985A (pt)
AU (1) AU2020388114A1 (pt)
BR (1) BR112022009142A2 (pt)
CA (1) CA3157731A1 (pt)
MX (1) MX2022006179A (pt)
WO (1) WO2021099579A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022251247A1 (en) * 2021-05-28 2022-12-01 Zeno Management, Inc. Macrocyclic compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
EP1904047B1 (en) 2005-07-07 2013-01-02 Abbott Laboratories Apoptosis promoters
EP2134684B1 (en) 2007-04-16 2017-08-02 AbbVie Inc. 7-substituted indole as mcl-1 inhibitors
CN101711235A (zh) 2007-04-16 2010-05-19 雅培制药有限公司 7-未取代的吲哚mcl-1抑制剂
TWI742074B (zh) 2016-04-22 2021-10-11 瑞典商阿斯特捷利康公司 Mcl-1抑制劑及其使用方法
TW201904976A (zh) 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Ｍｃｌ-１抑制劑及其使用方法
TWI781996B (zh) 2017-03-31 2022-11-01 瑞典商阿斯特捷利康公司 合成ｍｃｌ-１抑制劑之方法
KR20210070312A (ko) 2018-09-30 2021-06-14 지앙수 헨그루이 메디슨 컴퍼니 리미티드 인돌 거대 고리 유도체, 이의 제조 방법, 및 의약에서 이의 응용
WO2020103864A1 (en) 2018-11-22 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as mcl-1 inhibitors
WO2020151738A1 (en) 2019-01-23 2020-07-30 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic fused pyrrazoles as mcl-1 inhibitors
SG11202109367WA (en) 2019-03-08 2021-09-29 Zeno Management Inc Macrocyclic compounds

Also Published As

Publication number Publication date
KR20220103984A (ko) 2022-07-25
WO2021099579A1 (en) 2021-05-27
US20230021562A1 (en) 2023-01-26
CN114728985A (zh) 2022-07-08
AU2020388114A1 (en) 2022-07-14
CA3157731A1 (en) 2021-05-27
MX2022006179A (es) 2022-06-14
EP4061819A1 (en) 2022-09-28
JP2023502699A (ja) 2023-01-25

Similar Documents

Publication Publication Date Title
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR102018002152A8 (pt) Compostos, composições farmacêuticas e seus usos como inibidores de hiv
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112023000212A2 (pt) Éter macrocíclico contendo derivados de indol como inibidores de mcl-1
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112022002532A2 (pt) Compostos heterocíclicos como inibidores de quinase
BR112019004691A2 (pt) inibidores bicíclicos em espiro da interação menina-mll
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
BR112018002547A2 (pt) benzimidazóis substituídos, sua preparação e seu uso como produtos farmacêuticos
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112022025117A2 (pt) 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
BR112022009142A2 (pt) Derivados de indol macrocíclicos como inibidores de mcl-1
BR112022009754A2 (pt) Derivados macrocíclicos de sulfonila como inibidores de mcl-1
BR112018012307A2 (pt) derivados de pirrol[3,2-c]piridina-6-amino
BR112019025478A8 (pt) Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer
BR112022016444A2 (pt) Derivados de indol macrocíclico como inibidores de mcl-1